medac Pharma launch Bortezomib as new addition to Oncology portfolio

 

medac Pharma have strengthened their oncology portfolio with the launch of a new product, Bortezomib 3.5mg. It is available as a powder to be reconstituted as a solution for injection.

Bortezomib 3.5mg is available to order from Alloga with the order code: USP7153 / EAN code: 4037353018747.

About Bortezomib:
​​
​Bortezomib is licensed1 as monotherapy or in combination with other chemotherapy for the treatment of adult patients with progressive multiple myeloma, previously untreated multiple myeloma, induction treatment with previously untreated multiple myeloma and previously untreated mantle cell lymphoma.

References

  1. Bortezomib, Summary of Product Characteristics, medac Pharma https://www.medicines.org.uk/emc/product/13245/smpc

 

Get updates in your mailbox

By clicking "Subscribe" I confirm I have read and agree to the Privacy Policy.

About medac Pharma

medac Pharma is a privately owned, pharmaceutical company specialising in product development and the treatment of diseases within the key areas of oncology, autoimmune and urology.

medac GmbH was originally founded in Germany in 1970 and the UK operation was established in 1993. Since then we have become known for developing innovative products, especially in less common indications, which have resulted in a comprehensive portfolio of pharmaceutical products which help make a positive difference to the lives of your patients. We are committed to supplying therapeutic products and providing the diagnostic resources to identify diseases. We continue to invest in our manufacturing and logistic capabilities to ensure we meet the increasing demand of both healthcare professionals and patients’ needs.

Contact

Scion House Stirling University Innovation Park Stirling FK9 4NF

01786 458086

[email protected]

www.medacpharma.co.uk